269
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

ORCID Icon, ORCID Icon, , ORCID Icon, , , , , , , , & show all
Pages 2747-2754 | Received 16 Jan 2021, Accepted 03 May 2021, Published online: 20 May 2021

References

  • Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110(8):3064–3070.
  • Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–4699.
  • Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947–1954.
  • Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004;32(4):397–407.
  • Oran B, Wagner JE, DeFor TE, et al. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17(9):1327–1334.
  • Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347.
  • Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–839.
  • Pineault N, Abu-Khader A. Advances in umbilical cord blood stem cell expansion and clinical translation. Exp Hematol. 2015;43(7):498–513.
  • Fernandez MN, Regidor C, Cabrera R, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 2003;31(6):535–544.
  • Macmillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2009;43(6):447–454.
  • Mehta RS, Dave H, Bollard CM, et al. Engineering cord blood to improve engraftment after cord blood transplant. Stem Cell Investig. 2017;4:41.
  • Stasi R, Bosworth J, Rhodes E, et al. Thrombopoietic agents. Blood Rev. 2010;24(4–5):179–190.
  • McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227–2236.
  • Sun H, Tsai Y, Nowak I, et al. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86.
  • Cancer Therapy Evaluation Program. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. http://www.ctep.cancer.gov. Published: November 27, 2017.
  • Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15(6):825–828.
  • Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
  • Blume KF, Appelbaum FR. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. hematopoietic cell transplantation. Oxford, UK: Blackwell; 2004. p. 234–243.
  • Kristt D, Israeli M, Narinski R, et al. Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples. J Biomol Tech. 2005;16(4):380–391.
  • Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838–1846.
  • Liesveld JL, Phillips GL, Becker M, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013;19(12):1745–1752.
  • Tanaka T, Inamoto Y, Yamashita T, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(5):919–924.
  • Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):e65–e73.
  • Calmettes C, Vigouroux S, Tabrizi R, et al. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011;46(12):1587–1589.
  • Maximova N, Zanon D, Rovere F, et al. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. Int J Hematol. 2015;102(5):626–632.
  • Hartranft ME, Clemmons AB, DeRemer DL, et al. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. J Oncol Pharm Pract. 2017;23(1):10–17.
  • Battipaglia G, Ruggeri A, Brissot E, et al. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50(12):1574–1577.
  • Solh M, Brunstein C, Morgan S, et al. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant. 2011;17(5):710–716.
  • Solves P, Sanz J, Gomez I, et al. Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. Eur J Haematol. 2019;103(3):172–177.
  • Tang B, Huang L, Liu H, et al. Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation. Blood Adv. 2020;4(16):3829–3839.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.